Discussion about this post

User's avatar
VibeQuant's avatar

Interesting result. I would want to see it sector-neutral first. If it survives that, it feels like a solid slow-moving model feature.

Neural Foundry's avatar

Sharp insight on the R&D accounting mispricing. The fact that immediate expensing creates a systematic undervaluation is textbook inefficient markets hypothesis in action. I've seen this play out with biotech companeis where massive R&D spend tanks reported profitability but the intangible asset value is ignored by tradicional valuation models. The 3% annual premium holds even across market caps, which rules out the usual small-cap volatility excuse.

No posts

Ready for more?